[Skip to Content]

Upstate Active Clinical Trials

Study Title:

An Open-Label, Expanded Access Protocol for FirdapseĀ® (Amifampridine Phosphate; 3,4-Diaminopyridine Phosphate) Treatment in Patients with Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS) and Downbeat Nystagmus

What is the purpose of the study?

The purpose of this study is to allow your doctor to use amifampridine tablets to treat your disease symptoms.

Upstate Institutional Review Board (IRB) Number:

777408

Study/Protocol ID:

PROTOCOL NO: EAP-001

Study Phase:

PHASE IV

Patient Age Group:

Adults and Children

Principal Investigator:

Deborah Y Bradshaw

What is involved if I participate?

  • How long is the study?
    Until study drug is approved and becomes available by prescription
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No
  • What tests and procedures are involved?
    Informed Consent, Physical Examination, Neurological Examination, Vital Signs, Medication Review, Medical History Review, Clinical Laboratory Tests, Electrocardiogram

Other Information:

Contact: Muhammad M. Iqbal
Phone: (315) 464 - 1814
Email: iqbalmuh@upstate.edu

ClinicalTrials.Gov ID:

NCT02189720

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Muhammad M Iqbal
Phone: 315-464-1814
Email: iqbalmuh@upstate.edu

Return to Previous Page || Search Again

Top